A mixed-integer linear programming optimization model framework for capturing expert planning style in low dose rate prostate brachytherapy.
A mixed-integer linear programming optimization model framework for capturing expert planning style in low dose rate prostate brachytherapy. Phys Med Biol. 2019 Feb 15;: Authors: Babadagli ME, Sloboda R, Doucette J Abstract Low dose rate (LDR) brachytherapy is a minimally invasive form of radiation therapy, used to treat prostate cancer, and it involves permanent implantation of radioactive sources (seeds) inside of the prostate gland. Treatment planning in brachytherapy involves a decision making process for the placement of the sources in order to deliver an effective dose of radiation to cancerous tissue in the prostate while sparing the surrounding healthy tissue. Such a decision making process can be modeled as a mixed-integer linear programming (MILP) problem. In this paper, we introduce a novel MILP optimization model framework for interstitial LDR prostate brachytherapy designed to explicitly mimic the qualities of treatment plans produced manually by expert planners. Our approach involves incorporating a unique set of clinically important constraints, called spatial constraints, into the optimization model. Computational results for an initial model reflecting clinical practice at our cancer center show that the treatment plans produced largely capture the spatial and dosimetric characteristics of manual plans created by expert planners. PMID: 30769333 [PubMed - as supplied by publisher]
Conclusions: Fluoroscopy and 3D CT image-guided interstitial brachytherapy is feasible and appears to be a suitable treatment technique for patients with clinically localized prostate cancer after previous rectal resection and external beam radiation therapy. PMID: 31435432 [PubMed]
CONCLUSION: Despite a lack of prospective data, salvage reirradiation for prostate cancer recurrence can be proposed to highly selected patients and tumours. Prospective comparative studies are needed. PMID: 31421999 [PubMed - as supplied by publisher]
Prostatic artery embolization (PAE) is a safe and efficacious treatment for moderate to severe lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) refractory to medical therapy, including those in patients with multiple comorbidities who are poor surgical candidates or have large prostates (>80 mL) (1). Stereotactic body radiation therapy (SBRT) delivers high-dose radiation over a short time course, providing prostate cancer treatment outcomes similar to those in conventional external beam radiation therapy (EBRT) or brachytherapy (2).
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
Lung cancer patients undergoing radiotherapy during the time of a declared...Read more on AuntMinnie.comRelated Reading: Single-dose brachytherapy treats low-risk prostate cancer ASTRO: Prior authorization delays radiation treatment SABR plus surgery is effective for treating lung cancer Shorter radiotherapy works for prostate cancer treatment ASTRO updates guideline for lung cancer radiation therapy
In this study we evaluate the lesion detection efficacy of18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120 min after injection of a median dose of 311 MBq18F-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion sug...
CONCLUSIONS: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent. PMID: 31296421 [PubMed - as supplied by publisher]
CONCLUSIONS: Our results also demonstrate long-term overall survival benefits for EBRT + BT ± ADT, and greater bowel and bladder side effects over a decade, compared to RP. The RP group had advantage for long-term prostate-cancer specific mortality, compared to EBRT + ADT group. Thus, RP can provide superior cancer control with clear cost advantage for older men with high-risk disease. In terms of value proposition, our results support RP as preferred treatment option, compared to EBRT + ADT and EBRT + BT ± ADT for high-risk prostate cancer patients. PMID: 31285113 [PubMed - as supplied by publisher]
Prostate cancer brachytherapy: Can radiation pass to others?Prostate brachytherapy is a form of radiation therapy used to treat prostate cancer. The radioactive "seeds" are implanted into the prostate gland, so that radiation is delivered directly to the prostate, minimizing radiation to the surrounding tissue. Depending on the type of prostate cancer brachytherapy you receive, your [...]
Publication date: Available online 4 June 2019Source: European UrologyAuthor(s): Sebastian Berg, Alexander Cole, Quoc-Dien Trinh